Emerging Monoclonal Antibody Therapy for the Treatment of Acute Lymphoblastic Leukemia.

ABSTRACT: The treatment of adults with ALL has undergone tremendous progress over the past 15 years. The advances have been particularly marked with B-lineage ALL. The development of bispecific antibodies directed against CD19 ushered in a new era in overcoming persistent minimal disease in newly diagnosed ALL patients as well as successfully treating those with relapsed disease. The immune-conjugates targeting CD22 have also had a similarly impressive role in improving the outcome in such patients. These advances are now being extended to frontline regimens for B-lineage ALL, including the Philadelphia-chromosome-positive subtype. Over the past decade, the development of chimeric antigen receptor T-cell therapy (CAR-T) has ushered in a new era, opening up hope when none was available for patients w

SUBMITTER: Abuasab T 

PROVIDER: S-EPMC8536880 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature